SHC
Sotera Health Company · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow -3.4% ·
net new positions +20.0%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | -4 | 114.64M | $2.03B | +6 | −9 |
| Q1 2026 | 99 | +7 | 101.03M | $1.45B | +12 | −6 |
| Q4 2025 | 93 | +4 | 88.33M | $1.56B | +5 | — |
| Q3 2025 | 15 | -1 | 46.41M | $729.96M | — | −2 |
| Q2 2025 | 14 | +1 | 41.75M | $464.28M | +2 | −1 |
| Q1 2025 | 10 | +3 | 12.24M | $142.70M | +3 | — |
| Q4 2024 | 7 | -3 | 12.67M | $173.20M | — | −3 |
| Q3 2024 | 9 | -1 | 11.24M | $187.78M | +1 | −2 |
| Q2 2024 | 10 | — | 8.23M | $97.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 4.54M | +0.5% | $52.89M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.86M | +2.9% | $33.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.86M | +2.9% | $33.35M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 2.62M | 0.0% | $30.60M | 0.0% | Held | 3 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 1.13M | +21.5% | $13.22M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 396.20K | -73.3% | $4.59M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 396.20K | -73.3% | $4.59M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 396.20K | -73.3% | $4.59M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 396.20K | -73.3% | $4.59M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Gotham Asset Management ✦ | 330.14K | +35.9% | $3.85M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Marshall Wace ✦ | 164.79K | New | $1.92M | 0.0% | New | 1 | SEC ↗ |
| 12 | Marshall Wace ✦ | 164.79K | New | $1.92M | 0.0% | New | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 97.58K | +8.8% | $1.14M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 71.68K | New | $835,836 | 0.0% | New | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 71.68K | New | $835,836 | 0.0% | New | 1 | SEC ↗ |
| 16 | Millennium Management ✦ | 24.53K | New | $285,996 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.92M | 0.0% |
| Marshall Wace | $1.92M | 0.0% |
| Citadel Advisors | $835,836 | 0.0% |
| Citadel Advisors | $835,836 | 0.0% |
| Millennium Management | $285,996 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 293 holders, 275.22M shares, $3.76B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 294.51K sh · $5.45M
Officer, Director · 850.00K sh · $15.73M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology